INDICATIONS FASENRA is indicated for: the add-on maintenance treatment of patients with severe asthma aged 6 years and older and with an eosinophilic phenotype. FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus ...
Dosage Forms And Strengths FASENRA is a clear to opalescent, colorless to slightly yellow solution and may contain a few translucent or white to off-white particles. Injection: 30 mg/mL solution in a single-dose prefilled syringe. Injection: 30 mg/mL solution in a single-dose autoinjector ...
Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-li...
After the diagnostic assessment, each patient received medical indications and therapy for the control of asthma (according to the GINA guidelines) [33] and nasal symptoms (according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines) [34]. Patients who experienced uncontrolled ...